Literature DB >> 23986586

Middle East respiratory syndrome coronavirus spike protein delivered by modified vaccinia virus Ankara efficiently induces virus-neutralizing antibodies.

Fei Song1, Robert Fux, Lisette B Provacia, Asisa Volz, Markus Eickmann, Stephan Becker, Albert D M E Osterhaus, Bart L Haagmans, Gerd Sutter.   

Abstract

Middle East respiratory syndrome coronavirus (MERS-CoV) has recently emerged as a causative agent of severe respiratory disease in humans. Here, we constructed recombinant modified vaccinia virus Ankara (MVA) expressing full-length MERS-CoV spike (S) protein (MVA-MERS-S). The genetic stability and growth characteristics of MVA-MERS-S make it a suitable candidate vaccine for clinical testing. Vaccinated mice produced high levels of serum antibodies neutralizing MERS-CoV. Thus, MVA-MERS-S may serve for further development of an emergency vaccine against MERS-CoV.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23986586      PMCID： PMC3807317          DOI： 10.1128/JVI.01672-13

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  30 in total

1.  Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence.

Authors:  H Meyer; G Sutter; A Mayr
Journal:  J Gen Virol       Date:  1991-05       Impact factor: 3.891

2.  Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model.

Authors:  L S Wyatt; S T Shors; B R Murphy; B Moss
Journal:  Vaccine       Date:  1996-10       Impact factor: 3.641

3.  Anti-severe acute respiratory syndrome coronavirus spike antibodies trigger infection of human immune cells via a pH- and cysteine protease-independent FcγR pathway.

Authors:  Martial Jaume; Ming S Yip; Chung Y Cheung; Hiu L Leung; Ping H Li; Francois Kien; Isabelle Dutry; Benoît Callendret; Nicolas Escriou; Ralf Altmeyer; Beatrice Nal; Marc Daëron; Roberto Bruzzone; J S Malik Peiris
Journal:  J Virol       Date:  2011-07-20       Impact factor: 5.103

4.  Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region.

Authors:  Zhiwei Chen; Linqi Zhang; Chuan Qin; Lei Ba; Christopher E Yi; Fengwen Zhang; Qiang Wei; Tian He; Wenjie Yu; Jian Yu; Hong Gao; Xinming Tu; Agegnehu Gettie; Michael Farzan; Kwok-Yung Yuen; David D Ho
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

Review 5.  Clinical development of Modified Vaccinia virus Ankara vaccines.

Authors:  Sarah C Gilbert
Journal:  Vaccine       Date:  2013-03-21       Impact factor: 3.641

6.  Spike protein, S, of human coronavirus HKU1: role in viral life cycle and application in antibody detection.

Authors:  Che-Man Chan; Patrick C Y Woo; Susanna K P Lau; Herman Tse; Hong-Lin Chen; Feng Li; Bo-Jian Zheng; Ling Chen; Jian-Dong Huang; Kwok-Yung Yuen
Journal:  Exp Biol Med (Maywood)       Date:  2008-10-10

7.  Vaccines to prevent severe acute respiratory syndrome coronavirus-induced disease.

Authors:  Luis Enjuanes; Marta L Dediego; Enrique Alvarez; Damon Deming; Tim Sheahan; Ralph Baric
Journal:  Virus Res       Date:  2007-04-09       Impact factor: 3.303

Review 8.  The spike protein of SARS-CoV--a target for vaccine and therapeutic development.

Authors:  Lanying Du; Yuxian He; Yusen Zhou; Shuwen Liu; Bo-Jian Zheng; Shibo Jiang
Journal:  Nat Rev Microbiol       Date:  2009-02-09       Impact factor: 60.633

9.  Animal models and vaccines for SARS-CoV infection.

Authors:  Anjeanette Roberts; Elaine W Lamirande; Leatrice Vogel; Jadon P Jackson; Christopher D Paddock; Jeannette Guarner; Sherif R Zaki; Timothy Sheahan; Ralph Baric; Kanta Subbarao
Journal:  Virus Res       Date:  2007-05-11       Impact factor: 3.303

Review 10.  Expression, glycosylation, and modification of the spike (S) glycoprotein of SARS CoV.

Authors:  Shuo Shen; Timothy H P Tan; Yee-Joo Tan
Journal:  Methods Mol Biol       Date:  2007
View more
  92 in total

Review 1.  Coronaviruses: important emerging human pathogens.

Authors:  Christopher M Coleman; Matthew B Frieman
Journal:  J Virol       Date:  2014-03-05       Impact factor: 5.103

2.  Preventing drug-resistant tuberculosis transmission.

Authors:  Anastasia Koch; Helen Cox
Journal:  Lancet Infect Dis       Date:  2019-11-26       Impact factor: 25.071

Review 3.  Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease.

Authors:  Jasper F W Chan; Susanna K P Lau; Kelvin K W To; Vincent C C Cheng; Patrick C Y Woo; Kwok-Yung Yuen
Journal:  Clin Microbiol Rev       Date:  2015-04       Impact factor: 26.132

4.  A Highly Immunogenic and Protective Middle East Respiratory Syndrome Coronavirus Vaccine Based on a Recombinant Measles Virus Vaccine Platform.

Authors:  Anna H Malczyk; Alexandra Kupke; Steffen Prüfer; Vivian A Scheuplein; Stefan Hutzler; Dorothea Kreuz; Tim Beissert; Stefanie Bauer; Stefanie Hubich-Rau; Christiane Tondera; Hosam Shams Eldin; Jörg Schmidt; Júlia Vergara-Alert; Yasemin Süzer; Janna Seifried; Kay-Martin Hanschmann; Ulrich Kalinke; Susanne Herold; Ugur Sahin; Klaus Cichutek; Zoe Waibler; Markus Eickmann; Stephan Becker; Michael D Mühlebach
Journal:  J Virol       Date:  2015-09-09       Impact factor: 5.103

Review 5.  Prospects for a MERS-CoV spike vaccine.

Authors:  Yusen Zhou; Shibo Jiang; Lanying Du
Journal:  Expert Rev Vaccines       Date:  2018-08-09       Impact factor: 5.217

6.  Protective Efficacy of Recombinant Modified Vaccinia Virus Ankara Delivering Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein.

Authors:  Asisa Volz; Alexandra Kupke; Fei Song; Sylvia Jany; Robert Fux; Hosam Shams-Eldin; Jörg Schmidt; Christin Becker; Markus Eickmann; Stephan Becker; Gerd Sutter
Journal:  J Virol       Date:  2015-05-27       Impact factor: 5.103

7.  Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution.

Authors:  Xian-Chun Tang; Sudhakar S Agnihothram; Yongjun Jiao; Jeremy Stanhope; Rachel L Graham; Eric C Peterson; Yuval Avnir; Aimee St Clair Tallarico; Jared Sheehan; Quan Zhu; Ralph S Baric; Wayne A Marasco
Journal:  Proc Natl Acad Sci U S A       Date:  2014-04-28       Impact factor: 11.205

8.  Host species restriction of Middle East respiratory syndrome coronavirus through its receptor, dipeptidyl peptidase 4.

Authors:  Neeltje van Doremalen; Kerri L Miazgowicz; Shauna Milne-Price; Trenton Bushmaker; Shelly Robertson; Dana Scott; Joerg Kinne; Jason S McLellan; Jiang Zhu; Vincent J Munster
Journal:  J Virol       Date:  2014-06-04       Impact factor: 5.103

9.  Product of natural evolution (SARS, MERS, and SARS-CoV-2); deadly diseases, from SARS to SARS-CoV-2.

Authors:  Mohamad Hesam Shahrajabian; Wenli Sun; Qi Cheng
Journal:  Hum Vaccin Immunother       Date:  2020-08-12       Impact factor: 3.452

Review 10.  Middle East Respiratory Syndrome (MERS) Virus-Pathophysiological Axis and the Current Treatment Strategies.

Authors:  Abdullah M Alnuqaydan; Abdulmajeed G Almutary; Arulmalar Sukamaran; Brian Tay Wei Yang; Xiao Ting Lee; Wei Xuan Lim; Yee Min Ng; Rania Ibrahim; Thiviya Darmarajan; Satheeshkumar Nanjappan; Jestin Chellian; Mayuren Candasamy; Thiagarajan Madheswaran; Ankur Sharma; Harish Dureja; Parteek Prasher; Nitin Verma; Deepak Kumar; Kishneth Palaniveloo; Dheeraj Bisht; Gaurav Gupta; Jyotsana R Madan; Sachin Kumar Singh; Niraj Kumar Jha; Kamal Dua; Dinesh Kumar Chellappan
Journal:  AAPS PharmSciTech       Date:  2021-06-08       Impact factor: 3.246
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.